Law360, London: The European Fund and Asset Management Association (EFAMA) urged policymakers on 22 September 2025 to reform the crypto-assets regulatory framework to make capital markets more competitive.

This glossary contains summaries and definitions of some of the key investment funds terms and phrases. It also contains links to related Practice Notes. A Alternative investment fund (AIF) Any collective investment undertaking, including investment compartments of an AIF, that raises capital from a number of investors with a view to investing it in accordance with a defined investment policy for the benefit of those investors, and which is not a fund covered by Directive 2009/65/EC on the co-ordination of laws, regulations and administrative provisions relating to undertakings for collective investment in transferable securities (UCITS) (AIFMD, Directive 2011/61/EU, Art 4(1)(a)). An AIF may invest in traditional or alternative investments and may be private or listed, authorised or unauthorised. For more information (including scope and exemptions), see: Investment funds, asset management, and benchmarks (EU Law)—overview and Practice Note: EU AIFMD—essentials. Alternative investment fund manager (AIFM) A legal person whose regular business is managing one or more AIFs (AIFMD, Directive 2011/61/EU, Art 4(1)(b)). ‘Managing AIFs’ means performing at least portfolio management or risk management for

Law360: New rules for geographical indications covering agricultural products, wines and spirit drinks in the EU will kick in on 13 May 2024, part of the bloc's plan to boost uptake of the niche intellectual property right.

MLex: Trade secret protections, automated cookie consent and cyber incident reporting are the main outstanding questions in negotiations over the EU's digital simplification package, according to a 1 June 2026 document seen by MLex. EU governments are being asked to provide guidance on the three issues as talks continue on the EU's simplification plans.

Law360, London: The EU's carbon import levy on emissions-intensive goods such as aluminium and cement will allow importers to reduce the cost of the levy to mirror carbon allowances granted to EU producers based on benchmark values, according to guidance from the EU's executive.

This EU tracker covers case law in the following areas: • EU immigration policy • free movement of EU citizens • migration and asylum, with a special focus on legal immigration 2026 Case Judgment Date Key facts/Analysis Shamsi, Case C-877/24ECLI:EU:C:2026:397 13 May 2026 Summary: The request concerned the interpretation of Articles 6, 8 and 9 of Directive 2008/115/EC on common standards and procedures in Member States for returning illegally staying third-country nationals. The request was made in the context of proceedings between two third-country nationals and the Dutch Minister for Asylum and Migration concerning the lawfulness of return decisions issued against them.The Court held that:—Articles 6, 8 and 9 of Directive 2008/115/EC, read in combination with the principle of proportionality, must be interpreted as not precluding the adoption of a return decision against an illegally staying third-country national where, due to the execution of a long-term or lifelong sentence imposed on him or her, he or she will not be able either to leave the territory of the Member State concerned voluntarily

This Practice Note provides a high level overview of the common EU immigration policy, with a look at the key Directives enacted since the EU was given powers to legislate on this matter in the late 90s. This overview examines the scope of the legislation, the conditions laid down for admission and residence for Third Country Nationals (TCN), rights to equal treatment vested in TCNs, security of residence for TCN and family members as well as a brief look at the facilitation afforded by these Directives towards intra-EU free movement. The internal market ‘shall comprise an area without internal frontiers in which the free movement of goods, persons, services and capital is ensured in accordance with the provisions of the Treaties’ (Article 26 TFEU, formerly Article 14 EC Treaty). So long as the EU lacked express competence to regulate the flow and the movement of TCNs into and through Member States, the free movement of EU citizens (and family members) and services could not be fully and effectively secured. This changed with the advent of

MLex: Imports of continuous filament glass fiber products from China into the EU will be subject to definitive dumping tariffs of up 23%, the European Commission said on 25 November 2025. Similarly, the trade regulator set the level of duties to tackle unfair subsidization at 10.2%. The tariffs will start applying on 26 November 2025.

The EU has requested World Trade Organization (WTO) dispute consultations with China over China’s anti-subsidy investigation into certain EU dairy products. The EU claims that China’s investigation does not align with the Agreement on Subsidies and Countervailing Measures, as it lacks sufficient evidence of a countervailable subsidy, injury, and a causal link. The request was circulated to WTO members on 25 September 2024 and the parties have 60 days to resolve the matter through consultations before proceeding to adjudication.

The EU has initiated arbitration proceedings under Article 25 of the Dispute Settlement Understanding (DSU) to review the findings of a World Trade Organization (WTO) dispute panel in case DS611 involving the Enforcement of IP rights by China. As part of these proceedings, the EU circulated a Notice of Appeal, including the full text of the panel report, to WTO members on 24 April 2025. This marks the second arbitration proceeding under the Multi-Party Interim Appeal Arbitration Arrangement involving both China and the EU.

The European Commission has launched an initiative which highlights the detailed rules for the implementation of Regulation (EU) 2023/2411 on the protection of geographical indications (GI) for craft and industrial products. The initiative focuses on rules on registration, cancellation, and amendment of the product specification, rules on mutual assistance with and cooperation on controls and rules on the EU's symbol, fees and the IT system.

The EU-X-CT Cross-Border Clinical Trials Initiative, co-led by the European Forum for Good Clinical Practice (EFGCP) and European Federation of Pharmaceutical Industries and Associations (EFPIA) has met to discuss an initiative focussed on identifying barriers to participation in cross-border clinical trials and developing recommendations to overcome these challenges, with volunteers from diverse stakeholder groups actively involved. The first Public Stakeholders' Forum in Brussels, Belgium featured panel discussions with regulators, European Commission representatives, patients, and investigators sharing their perspectives on enabling cross-border access to clinical trials. EU-X-CT has also published a comprehensive summary of the key insights from the Public Stakeholders' Forum on its website. The initiative is now working on drafting recommendations for cross-border trial access based on feedback from EU-X-CT surveys and discussions at the Stakeholder Forum, which are expected to be shared for public comment by the end of 2024.